Pantoprazole and Other Proton Pump Inhibitors, Sleep, and Cardiovascular Safety: A Research Breakdown

This is an editorial, not an original study. The authors set out to weigh the evidence for and against a link between proton pump inhibitors (PPIs) and cardiovascular disease. They also raise a pathway that gets little attention in this debate. PPIs affect sleep, and poor sleep is tied to hypertension, metabolic problems, and cardiovascular risk. The paper asks whether disrupted sleep could be an indirect route through which long-term PPI use affects heart health.

Key Findings

The authors do not run new data. They pull together existing evidence and organize it into arguments for and against cardiovascular harm from PPIs.

Arguments for harm:

PPIs may raise blood pressure by lowering nitric oxide availability. This happens through reduced eNOS activity and buildup of ADMA, a compound that promotes vasoconstriction.
In a rat model, omeprazole given before cardiac ischemia and reperfusion increased cardiac injury markers and caused a 100 percent lethality rate, likely tied to reduced nitric oxide.
PPIs may lower heart muscle contractility. Cardiac tissue contains H+/K+-ATPase, the same pump PPIs block in the stomach. Blocking it in heart tissue may cause cellular acidosis and weaken contraction.
In animal studies, lansoprazole increased REM sleep duration. A case report found REM sleep behavior disorder that resolved when omeprazole was stopped and returned when lansoprazole was started.

Arguments against harm:

In patients with coronary disease, PPI use did not change ADMA levels compared to healthy volunteers, which weakens the nitric oxide theory.
A high dose IV pantoprazole regimen caused no meaningful change in heart function or blood flow in healthy volunteers.
Population data shows PPI use is rising while cardiovascular deaths are falling, though the authors note this may undercount stroke and pulmonary embolism, which they argue belong in the cardiovascular category.

The authors conclude that the evidence for PPIs as a cardiovascular risk factor is weak but plausible. They also note that most PPI safety studies have not looked at sleep pathways at all.

Background and Why This Matters

Nearly one in four adults will take a PPI at some point in their life, making this one of the most widely used drug classes worldwide. PPIs have long been considered very safe, but questions about kidney injury, nutrient absorption, and now cardiovascular risk have chipped away at that reputation. Sleep sits at an interesting crossroads here. Patients with obstructive sleep apnea often have reflux too, and treating that reflux with acid suppression tends to improve sleep quality even when the apnea-hypopnea index does not change. Since poor sleep independently drives hypertension and metabolic dysfunction, any drug that touches both acid suppression and sleep architecture deserves a closer look at how those two effects interact.

Comparison to Similar Past Research

This editorial builds directly on prior systematic reviews and umbrella reviews of PPI safety, such as Salvo et al.’s 2021 umbrella review of 42 meta-analyses. Those reviews found inconsistent results on cardiovascular risk, and this paper does not resolve that inconsistency. Instead, it adds a mechanistic layer by pulling together animal and cell studies on nitric oxide, ADMA, and cardiac H+/K+-ATPase that earlier reviews largely treated as background rather than a central focus.

Comparison to Contradicting Past Research

The clearest contradiction sits inside the paper itself. Ghebremariam et al. found elevated ADMA with PPI use in some populations, but a separate study in coronary disease patients found no ADMA change compared to healthy volunteers. Similarly, negative inotropic effects of pantoprazole shown in isolated myocardial tissue did not hold up in healthy volunteers given high dose IV pantoprazole. This is a recurring pattern in the PPI cardiovascular literature. Bench and animal findings often do not translate into measurable clinical effects in humans.

Strengths (Sleep Researcher Perspective)

The paper connects two research areas that are usually kept separate: cardiovascular pharmacology and sleep medicine. This cross-disciplinary framing is genuinely useful.
It correctly identifies that apnea-hypopnea index staying flat while sleep quality improves is a meaningful and underexplored finding. That gap deserves more attention than it usually gets.
It flags a real blind spot in the literature: almost no PPI safety studies measure sleep outcomes directly, despite sleep being a plausible mediator of cardiovascular risk.
The REM sleep behavior disorder case report is a useful clinical signal, even as a single case, because it points to a specific and testable mechanism involving the locus coeruleus.

Limitations (Sleep Researcher Perspective)

This is an editorial with no new data, no systematic search methodology, and no quality grading of the cited studies. Conclusions rest on selective citation rather than a structured review.
The sleep-cardiovascular link is asserted more than demonstrated. No study in this paper directly measures whether PPI-related sleep changes translate into blood pressure or cardiovascular outcome changes in the same patients.
Sleep studies referenced are thin. The REM finding comes from a single animal study and a single case report, not a controlled clinical trial.
Apnea-hypopnea index is treated as the main sleep metric, but it is a poor proxy for sleep quality or autonomic burden. More granular measures such as sleep fragmentation, oxygen desaturation index, or REM-specific apnea burden are not discussed.
The proposed nitric oxide and ADMA mechanism is inconsistent across the very studies cited, which the authors acknowledge but do not resolve.

Clinical Applicability

For now, this paper does not change prescribing practice. It supports what most clinicians already do: use PPIs when clearly indicated, avoid unnecessary long-term use, and reassess ongoing need periodically. Where it may shift practice is in patients with both cardiovascular risk and sleep complaints, particularly those with obstructive sleep apnea and reflux. In that group, treating reflux may improve sleep quality independent of apnea severity, and that improvement could carry downstream cardiovascular benefit worth watching. It also supports pairing CPAP with acid suppression rather than relying on either alone in patients with overlapping OSA and reflux. For patients at higher cardiovascular risk who need long-term acid suppression, H2 blockers remain a reasonable lower-risk alternative for milder GERD, though they are less effective at acid control. The main practical takeaway for a sleep clinic is to start asking about PPI use in patients presenting with new REM sleep behavior symptoms, since the case report suggests a discontinuation trial could be diagnostic.

Reference

Menezes-Rodrigues FS, Tallo FS, Herbella FAM, Caixeta A, Tonan RR, Bittencourt LRA, Tufik S, Andersen ML, Gehrke FS. Pantoprazole and other proton pump inhibitors, sleep, and cardiovascular safety: weak but plausible evidence. Rev Assoc Med Bras. 2026;72(7):e20260216. doi:10.1590/1806-9282.20260216